Skip to main content
Fig. 1 | Radiation Oncology

Fig. 1

From: Functional and mutational analysis after radiation and cetuximab treatment on prostate carcinoma cell line DU145

Fig. 1

Proliferation assay—Cell count-based growth curve from day 2 to day 9 with and without treatment, DU145 (a) and A431(b); Proliferation assay—relative cell count day 7 after radiation 4 Gy ± cetuximab 100 nM DU145 (c) significant reduction after radiation *p = 0.006 and radiation + cetuximab #p < 0.001, no significant after cetuximab ƚp = 0.35; no differences between radiation and radiation + cetuximab p > 0.05, radiation and cetuximab p = 0.73; significant between cetuximab and radiation + cetuximab p = 0.031 and A431 (d) significant reduction after radiation p = 0.02 and radiation + cetuximab p < 0.001, after cetuximab ƚƚp = 0.09; no differences between radiation and radiation + cetuximab p > 0.05, radiation and cetuximab p > 0.05 and between cetuximab and radiation + cetuximab p = 0.53; cetuximab 100 nM on day 2 and 3, radiation 4 Gy on day 3; (RT = radiation, Cet = cetuximab)

Back to article page